Eli Lilly expands output of obesity drug Foundayo as patient uptake climbs

Eli Lilly announced it is accelerating production of its newest GLP‑1 obesity treatment, Foundayo, after the company’s chief executive told CNBC that roughly one‑third of patients newly prescribed a GLP‑1 medication are now receiving the drug. The surge in demand has led the pharmaceutical firm to add capacity at its existing facilities and to explore additional sites for future manufacturing, according to CNBC.

Foundayo, which received FDA approval earlier this year, joins a crowded market of GLP‑1 agents that have reshaped the approach to weight management. Lilly’s statement underscores how quickly the product has moved from launch to becoming a significant share of the GLP‑1 landscape, a shift that mirrors the broader appetite for injectable and oral therapies that target the hormone glucagon‑like peptide‑1.

The rapid uptake of GLP‑1 drugs is rooted in a growing recognition of obesity as a chronic disease. Over the past decade, medications such as Novo Nordisk’s Wegovy and Mounjaro have demonstrated substantial weight‑loss results, prompting insurers and physicians to broaden prescribing practices. However, the popularity of these treatments has also strained supply chains, leading to periodic shortages and prompting manufacturers to invest heavily in new production lines. Lilly’s move to ramp up Foundayo manufacturing reflects a strategic effort to avoid similar bottlenecks and to capture market share from competitors.

Industry analysts note that scaling up production for biologics like GLP‑1 analogues is capital‑intensive and requires sophisticated bioreactor technology. Lilly’s existing facilities in Indiana and Ireland are being upgraded, and the company is evaluating partnerships with contract manufacturers to meet projected demand through 2030. If the current adoption rate holds, Foundayo could become a core revenue driver for Lilly’s specialty medicines segment.

The expansion also has implications for patients and payers. Greater supply may ease access constraints, potentially lowering out‑of‑pocket costs as competition intensifies. Yet, the high price tag typical of GLP‑1 therapies means that insurance coverage decisions will continue to shape how widely the drug is used across different demographic groups.

Overall, Lilly’s production boost signals confidence in Foundayo’s market potential and highlights the ongoing transformation of obesity treatment from a niche specialty to a mainstream therapeutic area.